临床试验:一项2期随机平台研究,用于评估代谢功能障碍相关的脂肪肝炎中的单疗法和组合治疗方案
Juan Frias1, Robert Schmouder2, Eric Lawitz3
1Velocity Clinical Research, Los Angeles, California, USA.
Alimentary pharmacology & therapeutics
|November 27, 2025
概括
对代谢功能障碍相关的脂肪肝炎 (MASH) 的组合治疗显示,肝脏脂肪和ALT的减少更大,但与单一治疗相比没有明显的额外益处,副作用是的增加.
科学领域:
- 肝病学和胃肠病学研究研究.
- 临床药理学和药物开发
- 代谢和肝病研究研究.
背景情况:
- 与代谢功能障碍相关的脂肪肝炎 (MASH) 为组合疗法提供了机会.
- 药物组合可能在MASH患者中提供添加剂或协同效果.
研究的目的:
- 在MASH患者中评估LYS006单疗与LYS006加 tropifexor联合治疗的安全性,疗效和药理学.
- 评估用于MASH治疗的组合药物治疗的潜力.
主要方法:
- 一个多中心的,开放的,平台的第二阶段研究随机选择了41名MASH患者.
- 患者接受了12周的LYS006单一治疗 (20毫克每天两次) 或组合治疗 (LYS006每天两次20毫克 + tropifexor每天一次200微克)
- 主要终点是安全性;次要终点包括疗效和药理动力学.
主要成果:
- 组合治疗组报告了高发烧率 (62%),这是Farnesoid X受体激活剂的已知副作用.
- 与LYS006单独治疗相比,联合治疗观察到氨酸胺转移酶 (ALT) 和肝脂肪的减少较大 (ALT:43%与13%相比;肝脂肪:37%与20%相比).
- 没有发现肝纤维化生物标志物的显著变化;然而,LYS006与Trophifexor的同时使用表明LYS006.6的血暴露较低.
结论:
- 总体而言,LYS006单疗法和托里菲克索结合疗法被很好地容忍,而是组合手臂的主要不良事件.
- 虽然组合治疗改善了ALT和肝脂肪的减少,但它没有显示出明显的额外益处,与单一治疗相比,其疗效与托里菲克索单一治疗相比.
- 该研究成功地展示了一种快速查方法,用于评估MASH治疗中的高效药物组合.
相关概念视频
Chronic Pancreatitis II: Collaborative Care
291
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
291
Drug Metabolism: Phase II Reactions
4.8K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
4.8K
Drug Metabolism: Phase I Reactions
4.5K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
4.5K
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
784
Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
784
Phase II Reactions: Glucuronidation
1.6K
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
1.6K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
161
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
161


